|
1.
|
Wu Y, Elshimali Y, Sarkissyan M, Mohamed
H, Clayton S and Vadgama JV: Expression of FOXO1 is associated with
GATA3 and Annexin-1 and predicts disease-free survival in breast
cancer. Am J Cancer Res. 2:104–115. 2012.PubMed/NCBI
|
|
2.
|
Hartman Z, Yang X, Glass O, Lei G, Osada
T, Dave SS, et al: HER2 overexpression elicits proinflammatory IL-6
autocrine signaling loop that is critical for tumorigenesis. Cancer
Res. 71:4380–4391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ulrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Hynes NE and Stern DF: The biology of
erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta.
1198:165–184. 1994.PubMed/NCBI
|
|
5.
|
Yarden Y: Biology of HER2 and its
importance in breast cancer. Oncology. 61:1–13. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Pegram MD, Konecny G and Slamon DJ: The
molecular and cellular biology of HER2/neu gene
amplification/overexpression and the clinical development of
Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat
Res. 103:57–75. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Zhang W, Ding W, Chen Y, Feng M, Ouyang Y,
Yu Y and He Z: Up-regulation of breast cancer resistance protein
plays a role in HER2-mediated chemoresistance through PI3K/Akt and
nuclear factor-kappa B signaling pathways in MCF-7 breast cancer
cells. Acta Biochim Biophys Sin (Shanghai). 43:647–653. 2011.
View Article : Google Scholar
|
|
8.
|
Siddiqa A, Long L, Li L, Marciniak R and
Kazhdan I: Expression of HER-2 in MCF-7 breast cancer cells
modulates anti-apoptotic proteins Survivin and Bcl-2 via the
extracellular signal-related kinase (ERK) and phosphoinositide-3
kinase (PI3K) signaling pathways. BMC Cancer. 8:1292008. View Article : Google Scholar
|
|
9.
|
Gemmete JJ and Mukherji SK: Trastuzumab
(herceptin). Am J Neuroradiol. 32:1373–1374. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Harbeck N, Pegram MD, Rüschoff J and Möbus
V: Targeted therapy in metastatic breast cancer: the HER2/neu
oncogene. Breast Care (Basel). 5(Suppl 1): 3–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hubalek M, Brunner C, Matthä K and Marth
C: Resistance to HER2-targeted therapy: mechanisms of trastuzumab
resistance and possible strategies to overcome unresponsiveness to
treatment. Wien Med Wochenschr. 160:506–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Cheng GZ, Zhang W, Sun M, Wang Q, Coppola
D, Mansour M, et al: Twist is transcriptionally induced by
activation of STAT3 and mediates STAT3 oncogenic function. J Biol
Chem. 283:14665–14673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lin L, Hutzen B, Zuo M, Ball S, Deangelis
S and Foust E: Novel STAT3 phosphorylation inhibitors exhibit
potent growth-suppressive activity in pancreatic and breast cancer
cells. Cancer Res. 70:2445–2454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Armanious H, Gelebart P, Mackey J, Ma Y
and Lai R: STAT3 upregulates the protein expression and
transcriptional activity of β-catenin in breast cancer. Int J Clin
Exp Pathol. 3:654–664. 2010.
|
|
15.
|
Zhong Z, Wen Z and Darnell J: Stat3: a
STAT3 family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hart JR, Liao L, Yates J and Vogt P:
Essential role of Stat3 in PI3K-induced oncogenic transformation.
Proc Natl Acad Sci USA. 108:13247–13252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yang Z, Cai J, Xie S, Li G, Song W, Yan Q,
Yan L and Zhang F: Therapeutic effects of signal transducer and
activator of transcription 3 siRNA on human breast cancer in
xenograft mice. Chin Med J. 124:1854–1861. 2011.PubMed/NCBI
|
|
18.
|
Yi EH, Lee CS, Lee JK, Lee YJ, Shin MK,
Cho CH, et al: STAT3-RANTES autocrine signaling is essential for
tamoxifen rsistance in human breast cancer cells. Mol Cancer Res.
11:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Marotta LC, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, et al: The JAK2/STAT3 signaling
pathway is required for growth of CD44+CD24−
stem cell-like breast cancer cells in human tumors. J Clin Invest.
121:2723–2735. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Oliveras-Ferraros C, Vazquez-Martin A,
Martin-Castillo B, Cufi S, Del Barco S, Lopez-Bonet E, et al:
Dynamic emergence of the mesenchymal CD44pos/CD24neg/low phenotype
in HER2-gene amplified breast cancer cells with de novo resistance
to trastuzumab (Herceptin). Biochem Biophys Res Commun. 397:27–33.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang
Z, et al: Twist2 contributes to breast cancer progression by
promoting an epithelial-mesenchymal transition and cancer stem-like
self-renewal. Oncogene. 30:4707–4720. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Berishaj M, Gao SP, Ahmed S, Leslie K,
Al-Ahmadie H, Gerald W, et al: Stat3 is tyrosine-phosphorylated
through the interleukin-6/glycoprotein 130/Janus kinase pathway in
breast cancer. Breast Cancer Res. 9:R322007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Schust J, Sperl B, Hollis A, Mayer T and
Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kong D, Li Y, Wang Z and Sarkar FH: Cancer
stem cells and epithelial-to-mesenchymal transition
(EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel).
3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sato T, Neilson LM, Peck AR, Liu C, Tran
T, Witkiewicz A, et al: Signal transducer and activator of
transcription-3 and breast cancer prognosis. Am J Cancer Res.
1:347–355. 2011.PubMed/NCBI
|
|
26.
|
Aggarwal BB, Sethi G, Ahn KS, Sandur SK,
Panday MK, Kunnunmakkara AB, et al: Targeting
signal-transducer-and-activator-of-transcription-3 for prevention
and therapy of cancer: modern target but ancient solution. Ann NY
Acad Sci. 1091:151–169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Masuda M, Wakasaki T, Suzui M, Toh S, Joe
AK and Weinstein IB: Stat3 orchestrates tumor development and
progression: the Achilles’ heel of head and neck cancers? Curr
Cancer Drug Targets. 10:117–126. 2010.PubMed/NCBI
|
|
28.
|
Takeda K, Noguchi K, Shi W, et al:
Targeted disruption of the mouse STAT3 gene leads to early
embryonic lethality. Proc Natl Acad Sci USA. 94:3801–3804. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Akira S: Roles of STAT3 defined by
tissue-specific gene targeting. Oncogene. 19:2607–2611. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ho JN, Kang GY, Lee SS, Kim J, Bae IH,
Hwang SG and Um HD: Bcl-XL and STAT3 mediate malignant actions of
gamma-irradiation in lung cancer cells. Cancer Sci. 101:1417–1423.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Hsu H-S, Lin JH, Hsu TW, Su K, Wang CW,
Yang KY, et al: Mesenchymal stem cells enhance lung cancer
initiation through activation of IL-6/JAK2/STAT3 pathway. Lung
Cancer. 75:167–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Floor S, van Staveren WC, Larsimont D,
Dumont JE and Maenhaut C: Cancer cells in epithelial-to-mesenchymal
transition and tumor propagating-cancer stem cells: distinct,
overlapping or same populations. Oncogene. 30:4609–4621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A and Zhou AY: The epithelial-mesenchymal transition generates
cells with properties of stem cells. Cell. 133:704–715. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Takebe N, Warren RQ and Ivy SP: Breast
cancer growth and metastasis: interplay between cancer stem cells,
embryonic signaling pathways and epithelial-to-mesenchymal
transition. Breast Cancer Res. 13:2112011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Al-Ejeh F, Smart CE, Morrison BJ,
Chenevix-Trench G, Lopez JA and Lakhani SR: Breast cancer stem
cells: treatment resistance and therapeutic opportunities.
Carcinogenesis. 32:650–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Blick T, Hugo H, Widodo E, Waltham M,
Pinto C and Mani SA: Epithelial mesenchymal transition traits in
human breast cancer cell lines parallel the CD44(hi/)CD24(lo/) stem
cell phenotype in human breast cancer. J Mammary Gland Biol
Neoplasia. 15:235–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
